Comparative Pharmacology
Head-to-head clinical analysis: E E S 400 versus ERYTHRA DERM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E E S 400 versus ERYTHRA DERM.
E.E.S. 400 vs ERYTHRA-DERM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin, a macrolide antibiotic, binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis. At high concentrations, it may also inhibit RNA synthesis.
Erythromycin, a macrolide antibiotic, binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis. It also exhibits anti-inflammatory and immunomodulatory effects, reducing neutrophil chemotaxis and bacterial lipase production.
Erythromycin ethylsuccinate 400 mg orally every 6 hours. For severe infections, up to 4 g/day in divided doses.
Apply a thin layer to the affected area(s) twice daily. For topical use only. Adult dose is 2% solution or ointment.
None Documented
None Documented
1.5-2.0 hours in adults with normal renal function; may be prolonged in hepatic impairment (up to 5-6 hours) but not significantly changed in renal disease.
Terminal elimination half-life of 2-4 hours; prolonged to 5-6 hours in hepatic impairment.
Primarily hepatic (biliary) excretion of unchanged drug and metabolites; approximately 2-5% renal excretion of unchanged drug; 5-15% fecal elimination.
Primarily biliary fecal elimination (60-70%); renal excretion of unchanged drug <15%.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic